Dr Stefan Anker: Patients With HFpEF Deserve a New Treatment

September 21, 2021 07:00pm

With empagliflozin, we now have evidence that another treatment for patients with heart failure with preserved ejection fraction (HFpEF) is possible, said Stefan Anker, MD, PhD, FESC, professor of cardiology, Department of Cardiology, Charité Campus Virchow Clinic, Berlin, Germany, and principal investigator of the EMPEROR-Preserved study.

A Timeline of COVID-19 Vaccine Developments for the Second Half of 2021
Study Finds Inverse Relationship Between OSA, Male Testosterone Levels
COVID-19 Symptoms Can Differentiate Respiratory Diseases, Study Says
Ruxolitinib Likely Safe, Effective in Chronic GVHD